Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Osteogenic sarcoma"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Differential Sensitivity of Taxol-induced Apoptosis in U2OS and SaOS2 Osteogenic Sarcoma Cells
Jung Hye Kim, Byung Rho Chin, Seong Yong Kim, Jae Ryong Kim, Suk Hwan Baek
Cancer Res Treat. 2003;35(2):148-153.   Published online April 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.2.148
AbstractAbstract PDF
PURPOSE
Taxol (Paclitaxel) is a new generation of chemotherapeutic drug proven to be effective in the treatment of many cancers. In this study, to further demonstrate the differential effect of the tumor suppressor gene, p53, on the Taxol-induced apoptosis in osteogenic sarcoma cell lines, we used p53-defected SaOS2 cells and wild type p53-expressed U2OS cells. MATERIALS AND METHODS: The cell viability was measured by the XTT assay. To examine whether the differential expressions of p53, in U2OS and SaOS2 cells, were associated with Taxol-induced apoptosis, DNA fragmentation assays were performed on both cytosolic and genomic DNA. Since the cleavage of poly (ADP-ribose) polymerase (PARP) is primarily responsible for apoptosis, the cleavage of PARP, and the expression of cyclin B1, polo-like kinase, Bax, Bcl-xL, Bcl-2 in U2OS and SaOS2 cells were compared by Western blot analyses. RESULTS: The cell viability of the p53-defected SaOS2 cells was markedly decreased with Taxol treatment. Whereas, the cell viabilities due to 6-mercaptopurine and adriamycin were no different between the U2OS and SaOS2 cells. Treatment with Taxol induced a ladder- like pattern of DNA fragments, which is a biochemical hallmark of apoptosis, consisting of multiples of approximately 180-200 base pairs, in a dose-dependent manner in the SaOS2 cells, but insignificantly with the U2OS cells. When the cells were treated with Taxol, the 89 kDa cleavage product of PARP clearly appeared as a function of time in the SaOS2 cells, but not in the U2OS cells. The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK. Bax, as a proapoptotic factor, was increased in the SaOS2cells, but the Bcl-xL and Bcl-2 were decreased when the cells were exposed to 10miceoM Taxol. CONCLUSION: From these results, it was concluded that p53-defected SaOS2 cells are much more sensitive to Taxol-induced apoptosis than p53-expressed U2OS cells.

Citations

Citations to this article as recorded by  
  • Imatinib-Functionalized Galactose Hydrogels Loaded with Nanohydroxyapatite as a Drug Delivery System for Osteosarcoma: In Vitro Studies
    Paulina Sobierajska, Benita Wiatrak, Paulina Jawien, Maciej Janeczek, Katarzyna Wiglusz, Adam Szeląg, Rafal J. Wiglusz
    ACS Omega.2023; 8(20): 17891.     CrossRef
  • Programmed cell death, redox imbalance, and cancer therapeutics
    Xiaofeng Dai, Danjun Wang, Jianying Zhang
    Apoptosis.2021; 26(7-8): 385.     CrossRef
  • High-Content, High-Throughput Screening for the Identification of Cytotoxic Compounds Based on Cell Morphology and Cell Proliferation Markers
    Heather L. Martin, Matthew Adams, Julie Higgins, Jacquelyn Bond, Ewan E. Morrison, Sandra M. Bell, Stuart Warriner, Adam Nelson, Darren C. Tomlinson, Maria A. Deli
    PLoS ONE.2014; 9(2): e88338.     CrossRef
  • The Time‐Dependent Serial Gene Response to Zeocin Treatment Involves Caspase‐Dependent Apoptosis in HeLa Cells
    Jooyeon Hwang, Young‐Youl Kim, Sungjin Huh, Junghee Shim, Chan Park, Kuchan Kimm, Dong Kug Choi, Tae‐Kyu Park, Soonhag Kim
    Microbiology and Immunology.2005; 49(4): 331.     CrossRef
  • Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment
    Eun-Kyoung Yim, Jun-Sang Bae, Seung-Bak Lee, Keun-Ho Lee, Chan-Joo Kim, Sung-Eun Namkoong, Soo-Jong Um, Jong-Sup Park
    Cancer Research and Treatment.2004; 36(6): 395.     CrossRef
  • 4,594 View
  • 64 Download
  • 5 Crossref
Close layer
Pharmacokinetics and Toxicities of High - Dose Methotrexate in the Treatment of Primary Osteogenic Sarcoma
Goo Hyun Baek, Soo Yong Lee, Seok Il Hong
J Korean Cancer Assoc. 1990;22(3):386-395.
AbstractAbstract PDF
From December 1989 to July l990, we have tried 70 courses of high-dose methotrexate therapy, which was combined with adriamycin and cisplatin, in the treatment of 13 patients with primary wteogenic sarcoma. The dosage of methotrexate in our protocol was 8 grams per square meter of body surface and the intravenous infusion was done for 4 hours. Using fluorescence polarization immunoassay (FPI) method, we measured the plasma level of methotrexate at 4, 5, 6, B, 24, 48 and 72 hours from the start of infusian. The toxicities were analyzed according to the WHO guidelines. The mean plasma level was 1343.89uM/L at 4 hours (S.D.: 474.63, range: 795.40 to 2870.00), 736.58 (S.D.:291.33, range: l53.00 to 1495.90) at 5 hours, 601.26 (S.D.:329.69, range:36.10 to 1251.20) at 6 hours, 353.44 (S.D.: 179.02, range: 3.60 to 720.23) at 8 hours, 7.32 (S.D.: 9.79, range: 0.08 to 68.50) at 24 hours, 0.40(S.D.: 0.55, range: 0.02 to 3.90) at 48 hours and 0.15 (S.D.: 0.09, range: 0.01 to 0.63) at 72 hours. Twenty two point nine percents at 24 hours and 17.1 percents at 48 hours needed increase of citrovorum factor rescue and 14.3 percents needed prolonged administration of citrovorum factor at 72 hours. Myelosuppression, alteration of hepatic function such as increase of sGOT and sGPT, and other infrequent toxicities were observed, but they were reversible and did not result in permanent dysfunction.
  • 1,879 View
  • 15 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP